AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
Related news for (ACIU)
- Today’s Top Performers: MoBot’s Market Review 10/03/25 03:00 PM
- AC Immune and Takeda Sign Exclusive Option and License Agreement Valued up to $2.1B
- AC Immune to Regain Global Rights to Crenezumab and Semorinemab
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
- AC Immune Announces Pricing of Underwritten Offering of Common Shares